Renal Lymphoma

Renal lymphoma is a malignant neoplasm of lymphoid origin that primarily involves the kidneys. It can occur as a primary renal tumor or, more commonly, as part of multicentric lymphoma with renal infiltration. In veterinary medicine, renal lymphoma is most frequently diagnosed in cats, where it is often associated with feline leukemia virus (FeLV) infection, though it can also occur in dogs. The disease is characterized by diffuse or nodular infiltration of the renal parenchyma by neoplastic lymphocytes, leading to progressive renal dysfunction, renomegaly, and eventual renal failure. Clinically, it presents with signs of chronic kidney disease (CKD) such as polyuria, polydipsia, weight loss, and azotemia, but may also manifest as an acute abdomen if there is renal rupture or ureteral obstruction. The condition is classified based on the anatomic location (primary vs. secondary), histologic grade (low, intermediate, high), and immunophenotype (B-cell, T-cell, or NK-cell). Renal lymphoma is a systemic disease in most cases, and staging is essential for prognosis and treatment planning.

The exact etiology of renal lymphoma is not fully understood, but several factors are implicated. In cats, infection with feline leukemia virus (FeLV) is a major risk factor, particularly for mediastinal and multicentric forms, but renal lymphoma can also occur in FeLV-negative cats. Feline immunodeficiency virus (FIV) infection may also increase the risk of lymphoma, though its direct role in renal lymphoma is less clear. In dogs, no specific viral etiology has been identified, but genetic predisposition, immune dysregulation, and environmental factors (e.g., exposure to tobacco smoke, herbicides) have been suggested. Chronic antigenic stimulation, such as from inflammatory bowel disease, has been proposed as a trigger for lymphoma development in some species. Molecularly, lymphomagenesis involves dysregulation of oncogenes (e.g., c-MYC, BCL-2) and tumor suppressor genes (e.g., p53), leading to uncontrolled lymphocyte proliferation and resistance to apoptosis. Chromosomal translocations and mutations in signaling pathways (e.g., JAK-STAT, NF-κB) are also implicated. In cats, FeLV integration into the host genome can activate cellular oncogenes, contributing to malignant transformation.

Renal lymphoma is relatively uncommon in dogs and cats compared to other forms of lymphoma. In cats, lymphoma accounts for up to 30% of all feline neoplasms, and renal involvement is seen in approximately 10-20% of feline lymphoma cases. It is more common in cats than in dogs. In cats, the median age at diagnosis is around 6-8 years, but it can occur in younger cats, especially those infected with FeLV. There is no strong breed predisposition, but Siamese and other Oriental breeds may be at higher risk for lymphoma in general. In dogs, renal lymphoma is rare, accounting for less than 5% of canine lymphomas. It can occur at any age, but middle-aged to older dogs (median age 7-9 years) are more commonly affected. No sex predilection is consistently reported. Geographic variation may reflect FeLV prevalence in cats; with widespread FeLV vaccination, the incidence of FeLV-associated lymphoma has decreased, but non-FeLV-associated lymphoma has increased. In dogs, certain breeds such as Golden Retrievers, Boxers, and Bullmastiffs have a higher incidence of lymphoma overall, but specific data for renal lymphoma are limited.

Renal lymphoma begins with the malignant transformation of lymphocytes, which then infiltrate the renal interstitium, often bilaterally. The neoplastic cells can arise from the kidney itself (primary) or spread hematogenously from other sites (secondary). The infiltration disrupts normal renal architecture, leading to tubular damage, interstitial fibrosis, and glomerular injury. As the tumor grows, it causes renomegaly, which may be diffuse or nodular. The functional consequences include decreased glomerular filtration rate (GFR), impaired tubular function, and reduced concentrating ability, resulting in polyuria and polydipsia. Progressive loss of nephrons leads to azotemia and eventually end-stage renal failure. Additionally, the tumor can cause ureteral obstruction if it compresses the ureters, leading to hydronephrosis and acute kidney injury. Paraneoplastic effects, such as hypercalcemia (due to secretion of parathyroid hormone-related protein) and immune-mediated hemolytic anemia, may occur. The neoplastic lymphocytes can also invade the renal vasculature, causing thrombosis and infarction. In cats, FeLV-associated lymphoma may have a more aggressive course due to viral oncogene expression and immunosuppression.

Predisposing factors for renal lymphoma include viral infections, particularly FeLV in cats, which is the most significant risk factor. FIV infection may also increase susceptibility. Genetic factors, such as certain major histocompatibility complex (MHC) haplotypes, may influence lymphoma risk in dogs. Age is a factor, as lymphoma is more common in middle-aged to older animals, though FeLV-positive cats may develop it at a younger age. Immunosuppression, whether from viral infection, chronic disease, or iatrogenic immunosuppressive therapy, can predispose to lymphoma. Environmental factors, such as exposure to environmental tobacco smoke, have been associated with an increased risk of lymphoma in cats. Chronic inflammatory conditions, such as inflammatory bowel disease, may lead to mucosal lymphoma in some cases, but this is more relevant to gastrointestinal lymphoma. In dogs, certain breeds (e.g., Golden Retrievers) have a higher baseline risk for lymphoma, but specific renal lymphoma risk is not well characterized.

Clinical signs of renal lymphoma are often nonspecific and may be insidious in onset. Common signs include polyuria and polydipsia (PU/PD), which result from impaired renal concentrating ability. Weight loss, anorexia, lethargy, and vomiting are frequently observed. As renal failure progresses, signs of uremia may develop, including oral ulceration, halitosis, and uremic breath. In some cases, the kidneys may be palpably enlarged on abdominal palpation, and renomegaly may be detected on physical examination. If ureteral obstruction occurs, acute anuria or oliguria may develop, leading to rapid clinical deterioration. Paraneoplastic hypercalcemia can cause additional signs such as muscle weakness, depression, and cardiac arrhythmias. In multicentric lymphoma, peripheral lymphadenopathy, hepatosplenomegaly, and other organ involvement may be present. Fever and anemia may also be noted. In cats, renal lymphoma may be associated with concurrent FeLV-related immunosuppression, leading to secondary infections.

Differential diagnoses for renal lymphoma include other renal neoplasms such as renal adenocarcinoma, nephroblastoma, and renal sarcoma. Chronic kidney disease (CKD) due to other causes (e.g., chronic interstitial nephritis, glomerulonephritis, amyloidosis) can present with similar signs of renal failure. Renal infections, such as pyelonephritis, can cause renomegaly and azotemia. Renal cysts or polycystic kidney disease may also cause renomegaly. In cats, feline infectious peritonitis (FIP) can cause granulomatous lesions in the kidneys. Other infiltrative diseases, such as renal amyloidosis or fungal infections (e.g., histoplasmosis), should be considered. Additionally, ureteral obstruction due to calculi or strictures can cause hydronephrosis and renomegaly. To differentiate, diagnostic imaging (ultrasound, CT) and fine-needle aspiration or biopsy are essential. Renal lymphoma typically shows hypoechoic or mixed echogenicity on ultrasound, whereas adenocarcinoma may have a more solid appearance. Cytology or histopathology is definitive.

The diagnostic approach to renal lymphoma begins with a thorough history and physical examination, with particular attention to palpation of the kidneys and peripheral lymph nodes. Baseline blood work, including complete blood count (CBC), serum biochemistry profile, and urinalysis, should be performed. If azotemia and isosthenuria are present, renal disease is confirmed. Next, abdominal imaging, preferably ultrasonography, is recommended to assess renal size, architecture, and the presence of masses or hydronephrosis. If renomegaly or renal masses are detected, fine-needle aspiration (FNA) of the kidney under ultrasound guidance is a minimally invasive method to obtain cytologic samples. Cytology may reveal a monomorphic population of large lymphocytes, consistent with lymphoma. However, FNA may be nondiagnostic in some cases, and a surgical biopsy (core biopsy or wedge biopsy) may be necessary for histopathologic confirmation and immunophenotyping. Staging for lymphoma should include thoracic radiographs (to check for mediastinal or pulmonary involvement), abdominal ultrasound (to evaluate other organs), and possibly bone marrow aspiration. Immunophenotyping (B-cell vs. T-cell) via flow cytometry or immunohistochemistry is important for prognosis and treatment planning. In cats, FeLV and FIV testing should be performed.

Laboratory findings in renal lymphoma often reflect renal dysfunction. The CBC may show anemia (non-regenerative due to chronic disease or regenerative if there is blood loss or hemolysis), leukocytosis or leukopenia, and thrombocytopenia. Serum biochemistry typically reveals azotemia (elevated BUN and creatinine), hyperphosphatemia, and possibly hypercalcemia (in paraneoplastic cases). Electrolyte abnormalities may include hyperkalemia (if oliguric renal failure) or hypokalemia (due to polyuria). Metabolic acidosis may be present. Urinalysis typically shows isosthenuria (USG 1.008-1.012) or minimally concentrated urine, proteinuria, and possibly hematuria or pyuria. The urine protein-to-creatinine ratio (UPC) may be elevated. Specific biomarkers such as symmetric dimethylarginine (SDMA) may be elevated earlier than creatinine. In cats, FeLV antigen and FIV antibody testing should be performed. If hypercalcemia is present, parathyroid hormone-related protein (PTHrP) levels may be elevated. Cytology of fine-needle aspirates from the kidney can show large, atypical lymphocytes with high nuclear-to-cytoplasmic ratios, prominent nucleoli, and mitotic figures.

Imaging plays a crucial role in the diagnosis and staging of renal lymphoma. On abdominal radiographs, bilateral renomegaly may be observed, but this is not specific. Ultrasonography is the most useful imaging modality: renal lymphoma typically appears as bilateral, diffuse renomegaly with hypoechoic renal cortices and loss of normal corticomedullary distinction. Nodular lesions may also be seen. Doppler ultrasound may show increased or decreased vascularity depending on the tumor. Hydronephrosis may be present if ureteral obstruction occurs. Thoracic radiographs are important to detect concurrent mediastinal lymphadenopathy or pulmonary involvement. Computed tomography (CT) provides more detailed anatomical information and can better characterize the extent of renal infiltration, as well as detect retroperitoneal lymphadenopathy. CT is also useful for planning radiation therapy if indicated. Magnetic resonance imaging (MRI) is rarely used for renal lymphoma but may be helpful in cases of suspected central nervous system involvement. In some cases, excretory urography or retrograde pyelography may be performed to evaluate ureteral patency, but these have largely been replaced by ultrasound and CT.

Cytologic evaluation of fine-needle aspirates from the kidney can be highly suggestive of lymphoma. The aspirate typically yields a population of large, immature lymphocytes with scant basophilic cytoplasm, round to irregular nuclei, coarse chromatin, and prominent nucleoli. Mitotic figures are often numerous. The cells may be intermediate to large in size, and the population is usually monomorphic. However, cytology cannot always distinguish between reactive lymphoid hyperplasia and lymphoma, and it does not provide information on tissue architecture. Histopathology from a core biopsy or surgical wedge biopsy is the gold standard for diagnosis. On histologic examination, there is diffuse or nodular infiltration of the renal interstitium by neoplastic lymphocytes, often with destruction of renal tubules and glomeruli. The tumor may be classified as low, intermediate, or high grade based on the degree of cellular atypia and mitotic activity. Immunohistochemistry (IHC) or flow cytometry can determine the immunophenotype (B-cell, T-cell, or NK-cell), which has prognostic significance. In cats, FeLV-associated lymphomas are often T-cell, while non-FeLV-associated ones may be B-cell. Special stains, such as CD3 (T-cell marker) and CD20 or PAX5 (B-cell markers), are used.

Treatment of renal lymphoma typically involves systemic chemotherapy, as the disease is often multicentric. The most commonly used protocol in cats is the COP protocol (cyclophosphamide, vincristine, prednisolone) or the UW-25 protocol (vincristine, cyclophosphamide, doxorubicin, L-asparaginase, prednisone). In dogs, the CHOP protocol (cyclophosphamide, doxorubicin, vincristine, prednisone) is standard. Doxorubicin is a key component but is nephrotoxic; however, in renal lymphoma, the benefit may outweigh the risk, and dose adjustments may be necessary if renal function is severely compromised. Supportive care includes fluid therapy to correct dehydration and electrolyte imbalances, antiemetics (e.g., maropitant at 1 mg/kg IV or SC q24h), and appetite stimulants (e.g., mirtazapine at 3.75 mg/cat PO q48h). If hypercalcemia is present, treatment with saline diuresis and furosemide (1-2 mg/kg IV or PO q8-12h) may be needed. In cases of ureteral obstruction, surgical intervention (ureteral stenting or nephrostomy tube) may be considered. Radiation therapy can be used for palliative treatment of large renal masses or for pain control. In cats with FeLV-associated lymphoma, antiviral therapy (e.g., zidovudine) may be considered, but its efficacy is limited. Nutritional support with a renal diet may be beneficial if CKD is present.

The prognosis for renal lymphoma is generally guarded to poor, but it depends on several factors. In cats, the response to chemotherapy is variable; those that achieve a complete remission may have a median survival of 6-12 months, while non-responders have a survival of weeks. FeLV-positive cats tend to have a poorer prognosis. In dogs, the prognosis is also guarded, with median survival times of 6-12 months with CHOP chemotherapy. Negative prognostic indicators include high-grade histology, T-cell immunophenotype (in dogs), presence of paraneoplastic hypercalcemia, severe azotemia at diagnosis, and poor performance status. Early diagnosis and treatment can improve outcomes. However, renal lymphoma is often diagnosed at an advanced stage due to the insidious onset of clinical signs. The presence of ureteral obstruction or acute kidney injury worsens the prognosis. Overall, the goal of treatment is to achieve remission and maintain quality of life, but cure is rare.

Follow-up for renal lymphoma involves regular monitoring of renal function and response to chemotherapy. During chemotherapy, a CBC and serum biochemistry profile should be checked before each treatment to assess for myelosuppression and renal toxicity. Blood pressure should be monitored, as hypertension is common in renal disease. Urinalysis and UPC ratio should be repeated periodically. Imaging, such as abdominal ultrasound, may be repeated every 1-3 months to assess tumor response. After completion of chemotherapy, re-staging is recommended at 3-month intervals for the first year, then every 6 months. If azotemia is present, IRIS staging guidelines for CKD should be followed, including monitoring of SDMA, creatinine, and electrolytes. Adjustments to chemotherapy doses may be necessary if renal function declines. Supportive care, such as renal diet and phosphate binders, should be continued as needed. Owners should be educated on signs of relapse, such as recurrence of PU/PD, weight loss, or vomiting, and prompt re-evaluation is advised.

Pearls: 1. Always consider renal lymphoma in any cat with renomegaly and azotemia, even if FeLV-negative. 2. Fine-needle aspiration of the kidney is a safe and minimally invasive diagnostic tool; do not hesitate to perform it if lymphoma is suspected. 3. In dogs, renal lymphoma is rare, but if a dog presents with bilateral renomegaly and lymphoma is confirmed elsewhere, renal involvement is likely. 4. Hypercalcemia in a lymphoma patient should prompt evaluation for renal lymphoma. 5. Chemotherapy can be effective, but monitor renal function closely, as doxorubicin is nephrotoxic. Pitfalls: 1. Do not assume that renomegaly is due to benign causes; always rule out neoplasia. 2. Avoid using nonsteroidal anti-inflammatory drugs (NSAIDs) in azotemic patients, as they can worsen renal function. 3. Do not delay chemotherapy while awaiting biopsy results if clinical suspicion is high; cytology may be sufficient to start treatment. 4. Be cautious with fluid therapy in patients with oliguric renal failure; monitor urine output. 5. Do not forget to test for FeLV/FIV in cats, as this affects prognosis and treatment decisions.

Chemotherapy protocols for renal lymphoma are based on those used for multicentric lymphoma. In cats, a commonly used protocol is the COP protocol: Cyclophosphamide 200-250 mg/m² PO or IV every 3 weeks, Vincristine 0.5-0.75 mg/m² IV weekly for 4 weeks then every 3 weeks, and Prednisolone 2 mg/kg PO q24h, tapering after 4 weeks. Alternatively, the UW-25 protocol includes L-asparaginase 400 IU/kg SC on day 1, Vincristine 0.5-0.75 mg/m² IV weekly, Cyclophosphamide 200 mg/m² IV every 3 weeks, Doxorubicin 25 mg/m² IV every 3 weeks, and Prednisone 2 mg/kg PO q24h. In dogs, the CHOP protocol is standard: Cyclophosphamide 200-250 mg/m² IV or PO on day 1, Doxorubicin 30 mg/m² IV every 3 weeks, Vincristine 0.5-0.75 mg/m² IV weekly, and Prednisone 2 mg/kg PO q24h, tapering. Dose reductions are necessary if azotemia is present; for example, doxorubicin should be reduced by 25% if creatinine is >2.5 mg/dL. Supportive medications include: Maropitant (Cerenia) 1 mg/kg IV or SC q24h for nausea; Ondansetron 0.5-1 mg/kg IV q12h; Mirtazapine 3.75 mg/cat PO q48h as an appetite stimulant; and for hypercalcemia, 0.9% NaCl IV at 60-100 ml/kg/day, Furosemide 1-2 mg/kg IV or PO q8-12h, and Prednisolone 2 mg/kg PO q24h. For ureteral obstruction, surgical intervention may be required. Always consult Plumb's Veterinary Drug Handbook for detailed dosing and monitoring.

Evidence-based literature on renal lymphoma is limited, but key studies include: In cats, a retrospective study by Vail et al. (1998) reported a median survival of 6 months in cats with renal lymphoma treated with chemotherapy. Another study by Mooney et al. (1989) found that FeLV-positive cats had a poorer response to treatment. In dogs, a study by Zandvliet et al. (2013) reported that dogs with renal lymphoma had a median survival of 9 months with CHOP-based chemotherapy. The ACVIM consensus statement on lymphoma in dogs and cats (2016) provides guidelines for diagnosis and treatment, emphasizing the importance of immunophenotyping and staging. The IRIS guidelines for CKD are relevant for managing renal dysfunction. There is no specific consensus on renal lymphoma, but extrapolation from multicentric lymphoma protocols is standard. Recent studies have explored the use of novel agents such as lomustine (CCNU) in resistant cases, but data are limited. Overall, the evidence base is weak, and treatment decisions should be individualized based on patient status and owner preferences.